The efficacy and safety of ASV therapy for acute heart failure

The efficacy and safety of ASV therapy for acute heart failure - ASV for acute heart failure

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008637

Enrollment

Registered

2012-08-13

Start date

2012-08-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute heart failure

Interventions

application of ASV for 2 hours after arrival

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) written consent 2) clinical diagnosis of AHF 3) pH <7.35

Exclusion criteria

Exclusion criteria: 1) shceduled invasive procedure i.e. surgery, PCI 2) general contraindication of ASV tendancy to vomit inablity to swallow pneumothorax or pneumomediatinum recent head trauma or surgery chronic hypoventilation

Design outcomes

Primary

Measure	Time frame
death in 7 days, 30 days	—

Secondary

Measure	Time frame
intubation, dyspnea score, blood gas analysis	—

Countries

Japan

Contacts

Public ContactShintaro Nakano

Saitama Medical University, International Medical Center Cardiology

snakano@gmail.com09048278924

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026